Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Tenofovir Alafenamide in Pregnancy

Source: Key Decisions in HIV Care
Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares key data and recommendations to support the use of TAF in pregnancy.
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Released: September 29, 2021

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores the data to support the use of tenofovir alafenamide in pregnancy.

Listen as she gives her perspectives on:

  • DHHS guideline recommendations for the use of TAF in pregnancy
  • Pharmacokinetic data to support adequate TAF concentrations throughout pregnancy
  • Available antiretroviral pregnancy registry information on the use of TAF in pregnancy
  • Data from the IMPAACT 2010 study to support the use of a TAF-containing regimen in pregnancy

Information on this Educational Activity

Faculty

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP

Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, has disclosed that she has received consulting fees from Theratechnologies and ViiV and fees for non-CME/CE services from Merck.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings